Global Focal Segmental Glomerulosclerosis Market to Reach $20.1 Billion by 2030
The global market for Focal Segmental Glomerulosclerosis estimated at US$12.8 Billion in the year 2023, is expected to reach US$20.1 Billion by 2030, growing at a CAGR of 6.6% over the period 2023-2030. Primary Disease, one of the segments analyzed in the report, is expected to record 6.7% CAGR and reach US$16.2 Billion by the end of the analysis period. Growth in the Secondary Disease segment is estimated at 6.3% CAGR for the next 7-year period.
The U.S. Market is Estimated at $3.9 Billion, While China is Forecast to Grow at 6.1% CAGR
The Focal Segmental Glomerulosclerosis market in the U.S. is estimated at US$3.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.5 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 5.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 41 Featured) -
AbbVie, Inc.
AstraZeneca PLC
ChemoCentryx, Inc.
GlaxoSmithKline PLC
Novartis AG
Pfizer, Inc.
Retrophin, Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Variant Pharmaceuticals, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Focal Segmental Glomerulosclerosis - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Focal Segmental Glomerulosclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Focal Segmental Glomerulosclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Focal Segmental Glomerulosclerosis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 11: World Recent Past, Current & Future Analysis for Primary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Primary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Primary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Secondary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Secondary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Secondary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
JAPAN
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
CHINA
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
EUROPE
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Focal Segmental Glomerulosclerosis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for Focal Segmental Glomerulosclerosis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
FRANCE
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: France Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: France 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
GERMANY
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Germany 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Italy 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
UNITED KINGDOM
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: UK Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: UK 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Europe Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Europe 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Rest of Europe Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Rest of Europe 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Focal Segmental Glomerulosclerosis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Asia-Pacific Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Asia-Pacific 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Asia-Pacific Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Asia-Pacific 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 86: Rest of World Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of World Historic Review for Focal Segmental Glomerulosclerosis by Disease Type - Primary and Secondary Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of World 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Type - Percentage Breakdown of Value Sales for Primary and Secondary for the Years 2014, 2024 & 2030
TABLE 89: Rest of World Recent Past, Current & Future Analysis for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of World Historic Review for Focal Segmental Glomerulosclerosis by Disease Management - Treatment and Diagnosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of World 16-Year Perspective for Focal Segmental Glomerulosclerosis by Disease Management - Percentage Breakdown of Value Sales for Treatment and Diagnosis for the Years 2014, 2024 & 2030